eISSN 2288-3657
pISSN 2288-3649
pISSN 2288-3649
The safety profile of the 43 patients with metastatic CRC who received apatinib plus PD-1 blockades treatment
| Adverse reactions | Total | Grade 1-2 | Grade 3-4 |
|---|---|---|---|
| Fatigue | 33 (76.7) | 29 (67.4) | 4 (9.3) |
| Hypertension | 31 (72.1) | 25 (58.1) | 6 (14.0) |
| Diarrhea | 27 (62.8) | 24 (55.8) | 3 (7.0) |
| Hand-foot syndrome | 22 (51.2) | 17 (39.5) | 5 (11.6) |
| Nausea and vomiting | 19 (44.2) | 16 (37.2) | 3 (7.0) |
| Rash | 15 (34.9) | 13 (30.2) | 2 (4.7) |
| Hepatotoxicity | 13 (30.2) | 10 (23.3) | 3 (7.0) |
| Pneumonia | 11 (25.6) | 10 (23.3) | 1 (2.3) |
| Proteinuria | 9 (20.9) | 7 (16.3) | 2 (4.7) |
| RCCEP | 7 (16.3) | 7 (16.3) | 0 (0.0) |
| Hematologic toxicity | 4 (9.3) | 4 (9.3) | 0 (0.0) |
Values are presented as number (%). CRC, colorectal cancer; PD-1, programmed cell death protein 1; RCCEP, reactive cutaneous capillary endothelial proliferation.
J Cancer Prev 2023;28:106~114 https://doi.org/10.15430/JCP.2023.28.3.106
© J Cancer Prev
© Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd